Adding dostarlimab improves progression-free survival in endometrial cancer
For patients with primary advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel increases progression-free survival versus carboplatin-paclitaxel alone, according to a study published online March ...
Apr 4, 2023
0
2